Provides products and services for dialysis patients. Manages hospitals and outpatient clinics. Now — the numbers.
This is an established company with proven profits.
An average decline of 12% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
The gap is $12.0B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 20.9× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
It pays out $1.22 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales fell about 12% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.